Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $127.43 USD
Change Today +1.97 / 1.57%
Volume 414.3K
ALNY On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 07/31/15 All times are local (Market data is delayed by at least 15 minutes).

alnylam pharmaceuticals inc (ALNY) Snapshot

Open
$126.55
Previous Close
$125.46
Day High
$130.00
Day Low
$124.82
52 Week High
06/23/15 - $140.00
52 Week Low
08/1/14 - $52.35
Market Cap
10.7B
Average Volume 10 Days
550.2K
EPS TTM
$-2.11
Shares Outstanding
84.3M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ALNYLAM PHARMACEUTICALS INC (ALNY)

alnylam pharmaceuticals inc (ALNY) Related Businessweek News

View More BusinessWeek News

alnylam pharmaceuticals inc (ALNY) Details

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel therapeutics based on RNA interference. The company’s clinical development programs include Patisiran and Revusiran, which are in Phase III clinical trials for the treatment of transthyretin-mediated amyloidosis; ALN-AT3 that is in Phase I clinical trial for hemophilia and rare bleeding disorders; ALN-CC5, which is in Phase I/II clinical trial for the treatment of complement-mediated diseases; and ALN-PCSsc that is in Phase I clinical trial for hypercholesterolemia. Its product development programs also include ALN-AS1 for the treatment of hepatic porphyrias; ALN-AAT for the treatment of alpha-1 antitrypsin deficiency liver disease; ALN-GO1 for the treatment of primary hyperoxaluria type 1; ALN-TMP for the treatment of beta-thalassemia and iron-overload disorders; ALN-AC3 for the treatment of hypertriglyceridemia; ANGPTL3 for the treatment of hypertriglyceridemia and mixed hyperlipidemia; ALN-AGT for the treatment of hypertensive disorders of pregnancy, including preeclampsia; ALN-HBV for the treatment of Hepatitis B Virus; ALN-HDV for the treatment of HDV infection; and ALN-PDL for the treatment of chronic liver infections. The company has strategic alliances and collaboration agreements with Genzyme Corporation; The Medicines Company; Monsanto Company; F. Hoffmann-La Roche Ltd; Isis Pharmaceuticals, Inc.; Novartis Pharma AG; Tekmira Pharmaceuticals Corporation; The University of British Columbia; Acuitas Therapeutics Inc.; Takeda Pharmaceutical Company Limited; Protiva Biotherapeutics, Inc.; Biogen Idec Inc.; Medtronic, Inc.; Kyowa Hakko Kirin Co., Ltd.; Cubist Pharmaceuticals, Inc.; and Ascletis BioScience Co., Ltd. Alnylam Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Cambridge, Massachusetts.

256 Employees
Last Reported Date: 02/13/15
Founded in 2002

alnylam pharmaceuticals inc (ALNY) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: $689.6K
President and Chief Operating Officer
Total Annual Compensation: $515.0K
Vice President of Finance and Treasurer
Total Annual Compensation: $257.2K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $463.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $210.8K
Compensation as of Fiscal Year 2014.

alnylam pharmaceuticals inc (ALNY) Key Developments

Alnylam Pharmaceuticals, Inc. - Special Call

To consider ALN-HBV for the treatment of Hepatitis B Virus (HBV) Infection

Alnylam Initiates Phase 1/2 Clinical Trial for ALN-AAT, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease)

Alnylam Pharmaceuticals, Inc. announced that it has initiated a Phase 1/2 clinical trial with ALN-AAT, a subcutaneously administered investigational RNAi therapeutic targeting alpha-1 antitrypsin (AAT) for the treatment of AAT deficiency-associated liver disease (alpha-1 liver disease). The Phase 1/2 trial will be conducted initially in normal healthy volunteers, and, then, in patients with alpha-1 liver disease. Initiation of this trial is based on encouraging pre-clinical data presented at the Digestive Disease Week (DDW) meeting May 16 - 19, 2015. The company expects to present initial clinical data from this trial in early 2016. ALN-AAT is a subcutaneously administered investigational RNAi therapeutic that utilizes Alnylam’s proprietary ESC-GalNAc-siRNA conjugate delivery technology. ESC-GalNAc-siRNA conjugates are designed to achieve targeted delivery of RNAi therapeutics to hepatocytes through uptake by the asialoglycoprotein receptor, and enable subcutaneous dosing with increased potency and durability and a wide therapeutic index. As per the filed CTA, the Phase 1/2 trial of ALN-AAT is a randomized, single-blind, placebo-controlled study being conducted in three parts. Parts A and B are single-dose (Part A) and multi-dose (Part B), dose-escalation studies, designed to enroll up to a total of 48 healthy adult volunteers. Part C will be a multi-dose study designed to enroll up to a total of 24 adults with alpha-1 liver disease and mild-to-moderate liver fibrosis. The primary objective of the study is to evaluate safety and tolerability of single and multiple subcutaneous doses of ALN-AAT. Secondary objectives include evaluation of pharmacokinetics and clinical activity for ALN-AAT as measured by knockdown of serum AAT. In addition, biopsies will be obtained from subjects with alpha-1 liver disease to quantify the effects of treatment on levels of periodic acid-Schiff (PAS)-stained globules, a measure of misfolded AAT accumulation observed in the livers of alpha-1 liver disease patients.

Alnylam Pharmaceuticals, Inc. - Special Call

RNAi Roundtable: ALN-AT3 for the treatment of Hemophilia and Rare Bleeding Disorders

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALNY:US $127.43 USD +1.97

ALNY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Galena Biopharma Inc $1.64 USD -0.02
Isis Pharmaceuticals Inc $54.93 USD +1.76
Regulus Therapeutics Inc $8.20 USD -0.06
Sarepta Therapeutics Inc $31.92 USD +0.16
View Industry Companies
 

Industry Analysis

ALNY

Industry Average

Valuation ALNY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 172.0x
Price/Book 7.2x
Price/Cash Flow NM Not Meaningful
TEV/Sales 159.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALNYLAM PHARMACEUTICALS INC, please visit www.alnylam.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.